Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
Sponsor: Bo Lu
Summary
The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.
Official title: A Multi-Center Pilot Biomarker Study With Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
125
Start Date
2024-04-19
Completion Date
2030-04-19
Last Updated
2025-06-19
Healthy Volunteers
No
Conditions
Interventions
Curative Radiotherapy
Radiation dose of 45 Gy or higher
Immunotherapy
checkpoint inhibitor per PI discretion
Locations (3)
University of Missouri - Ellis Fischel Cancer Center
Columbia, Missouri, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
University of Rochester Medical Center
Rochester, New York, United States